共 169 条
[1]
Cuchel M(2014)Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society Eur Heart J 35 2146-2157
[2]
Bruckert E(2020)Phenotypical, clinical, and molecular aspects of adults and children with homozygous familial hypercholesterolemia in Iberoamerica Arterioscler Thromb Vasc Biol 40 2508-2515
[3]
Ginsberg HN(2015)Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment Eur Heart J 381 40-46
[4]
Alves AC(2016)European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk Eur Heart J 375 998-1006
[5]
Alonso R(2013)Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 14 19-27
[6]
Diaz-Diaz JL(2010)Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 33 197-208
[7]
Wiegman A(2013)Lipoprotein apheresis: state of the art and novelties Atheroscler Suppl 152 519-526
[8]
Gidding SS(2015)Lipoprotein apheresis Cardiol Clin 6 331-339
[9]
Watts GF(2000)The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels Atherosclerosis 270 42-48
[10]
Landmesser U(2012)Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia J Clin Lipidol 299 24-31